Analysts Set LeMaitre Vascular, Inc. (NASDAQ:LMAT) Target Price at $94.57

LeMaitre Vascular, Inc. (NASDAQ:LMAT - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the nine analysts that are currently covering the company, Marketbeat.com reports. Two investment analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating on the company. The average 12-month target price among brokers that have issued a report on the stock in the last year is $94.63.

A number of equities analysts have recently weighed in on the company. StockNews.com lowered LeMaitre Vascular from a "buy" rating to a "hold" rating in a research report on Friday, December 13th. Oppenheimer reaffirmed an "outperform" rating and set a $93.00 target price (up from $90.00) on shares of LeMaitre Vascular in a research report on Friday, November 1st. Barrington Research raised their target price on LeMaitre Vascular from $92.00 to $93.00 and gave the company an "outperform" rating in a research report on Friday, November 1st. Finally, Wells Fargo & Company started coverage on LeMaitre Vascular in a research report on Thursday. They set an "equal weight" rating and a $95.00 target price for the company.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of LMAT. Freestone Grove Partners LP bought a new position in LeMaitre Vascular in the fourth quarter valued at about $292,000. Monashee Investment Management LLC bought a new position in shares of LeMaitre Vascular in the fourth quarter worth about $3,686,000. Northern Trust Corp raised its stake in shares of LeMaitre Vascular by 5.1% in the fourth quarter. Northern Trust Corp now owns 327,815 shares of the medical instruments supplier's stock worth $30,205,000 after buying an additional 15,843 shares during the period. Tudor Investment Corp ET AL raised its stake in shares of LeMaitre Vascular by 111.8% in the fourth quarter. Tudor Investment Corp ET AL now owns 39,012 shares of the medical instruments supplier's stock worth $3,595,000 after buying an additional 20,597 shares during the period. Finally, Susquehanna Fundamental Investments LLC bought a new position in shares of LeMaitre Vascular in the fourth quarter worth about $351,000. 84.64% of the stock is owned by institutional investors.

LeMaitre Vascular Trading Up 1.7 %

LMAT stock traded up $1.66 during trading on Tuesday, hitting $98.65. The company had a trading volume of 223,618 shares, compared to its average volume of 155,624. The stock has a market cap of $2.22 billion, a PE ratio of 53.91, a PEG ratio of 2.19 and a beta of 0.96. LeMaitre Vascular has a one year low of $59.87 and a one year high of $109.58. The business has a 50-day moving average of $95.99 and a 200-day moving average of $93.49.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.